{"entity":{"id":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","kind":"paper","name":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","aka":[],"tldr":"Adding two years of abiraterone to hormone therapy and radiotherapy for high-risk localised or node-positive prostate cancer halved the risk of metastases and cut deaths by 40 percent, while adding enzalutamide on top brought only extra toxicity.","summary":"Meta-analysis of two STAMPEDE comparisons including 1,974 men with high-risk non-metastatic prostate cancer (node-positive, or node-negative with at least two of T3/4, Gleason 8 to 10, PSA 40 or more) randomised to androgen deprivation with or without two years of abiraterone (with enzalutamide in the second comparison).\n\nSix-year metastasis-free survival was 82 versus 69 percent (hazard ratio 0.53) and overall survival 86 versus 77 percent (hazard ratio 0.60); enzalutamide added toxicity without efficacy.","asOf":"2026-09-17","links":[{"label":"Lancet 2022","url":"https://doi.org/10.1016/S0140-6736(21)02437-5"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34953525/"}],"tags":[],"related":[],"cancers":["prostate-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","enzalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["stampede"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2022,"doi":"10.1016/S0140-6736(21)02437-5","pmid":"34953525","authors":"Attard G, Murphy L, Clarke NW, et al.","paperType":"rct","findings":["Six-year metastasis-free survival 82 percent vs 69 percent; hazard ratio 0.53.","Six-year overall survival 86 percent vs 77 percent; hazard ratio 0.60."],"whatItMeans":"Two years of abiraterone with androgen deprivation and radiotherapy is the standard for very high-risk and node-positive localised prostate cancer.","caveats":["Most men received radiotherapy; benefit after prostatectomy is less certain.","Staging was by conventional imaging."],"changedPractice":true,"participants":1974},"route":"/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/","neighbours":{"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"}],"trial":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}